HUP0202621A2 - Javított farmakológiai tulajdonságokkal rendelkező, parenteralis felhasználásra szolgáló ösztramusztin-foszfát készítmények - Google Patents
Javított farmakológiai tulajdonságokkal rendelkező, parenteralis felhasználásra szolgáló ösztramusztin-foszfát készítményekInfo
- Publication number
- HUP0202621A2 HUP0202621A2 HU0202621A HUP0202621A HUP0202621A2 HU P0202621 A2 HUP0202621 A2 HU P0202621A2 HU 0202621 A HU0202621 A HU 0202621A HU P0202621 A HUP0202621 A HU P0202621A HU P0202621 A2 HUP0202621 A2 HU P0202621A2
- Authority
- HU
- Hungary
- Prior art keywords
- parenteral use
- pharmacological properties
- formulations
- improved pharmacological
- estramustine phosphate
- Prior art date
Links
- 229960004750 estramustine phosphate Drugs 0.000 title abstract 2
- ADFOJJHRTBFFOF-RBRWEJTLSA-N estramustine phosphate Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)OP(O)(O)=O)[C@@H]4[C@@H]3CCC2=C1 ADFOJJHRTBFFOF-RBRWEJTLSA-N 0.000 title abstract 2
- 230000000144 pharmacologic effect Effects 0.000 title abstract 2
- 238000009472 formulation Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 238000002360 preparation method Methods 0.000 abstract 2
- 229920000858 Cyclodextrin Polymers 0.000 abstract 1
- 102000008100 Human Serum Albumin Human genes 0.000 abstract 1
- 108091006905 Human Serum Albumin Proteins 0.000 abstract 1
- 229960001842 estramustine Drugs 0.000 abstract 1
- FRPJXPJMRWBBIH-RBRWEJTLSA-N estramustine Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 FRPJXPJMRWBBIH-RBRWEJTLSA-N 0.000 abstract 1
- 150000002170 ethers Chemical class 0.000 abstract 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 abstract 1
- 125000004964 sulfoalkyl group Chemical group 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/38—Albumins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pulmonology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9921954.5A GB9921954D0 (en) | 1999-09-16 | 1999-09-16 | Formulations for parenteral use of estramustine phosphate with improved pharmacological properties |
| PCT/EP2000/007679 WO2001019338A1 (en) | 1999-09-16 | 2000-08-03 | Formulations for parenteral use of estramustine phosphate with improved pharmacological properties |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUP0202621A2 true HUP0202621A2 (hu) | 2002-12-28 |
Family
ID=10861066
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU0202621A HUP0202621A2 (hu) | 1999-09-16 | 2000-08-03 | Javított farmakológiai tulajdonságokkal rendelkező, parenteralis felhasználásra szolgáló ösztramusztin-foszfát készítmények |
Country Status (20)
| Country | Link |
|---|---|
| EP (1) | EP1212040A1 (ru) |
| JP (1) | JP2003509355A (ru) |
| KR (1) | KR20020059405A (ru) |
| CN (1) | CN1177583C (ru) |
| AU (1) | AU777763B2 (ru) |
| BR (1) | BR0014063A (ru) |
| CA (1) | CA2385063A1 (ru) |
| CZ (1) | CZ2002943A3 (ru) |
| EA (1) | EA005308B1 (ru) |
| GB (1) | GB9921954D0 (ru) |
| HK (1) | HK1047227A1 (ru) |
| HU (1) | HUP0202621A2 (ru) |
| IL (1) | IL148409A0 (ru) |
| MX (1) | MXPA02002859A (ru) |
| NO (1) | NO20021306L (ru) |
| NZ (1) | NZ517631A (ru) |
| PL (1) | PL353954A1 (ru) |
| SK (1) | SK3452002A3 (ru) |
| WO (1) | WO2001019338A1 (ru) |
| ZA (1) | ZA200201743B (ru) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7658913B2 (en) | 2005-11-28 | 2010-02-09 | Verrow Pharmaceuticals, Inc. | Compositions useful for reducing nephrotoxicity and methods of use thereof |
| EP2620023B1 (en) | 2010-09-21 | 2018-02-28 | Telefonaktiebolaget LM Ericsson (publ) | Air-interface timing synchronization sharing |
| WO2019094819A2 (en) * | 2017-11-09 | 2019-05-16 | Abon Pharmaceuticals, Llc | Intravenous delivery systems for chemotherapy drugs |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS59108800A (ja) * | 1982-12-13 | 1984-06-23 | Japan Atom Energy Res Inst | 誘導ミサイル作用および制癌剤の徐放性機能をもつ微粒子 |
| KR0166088B1 (ko) * | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| US5602112A (en) * | 1992-06-19 | 1997-02-11 | Supergen, Inc. | Pharmaceutical formulation |
| GB9419153D0 (en) * | 1994-09-22 | 1994-11-09 | Erba Carlo Spa | Estramustine formulations with improved pharmaceutical properties |
| US20020039594A1 (en) * | 1997-05-13 | 2002-04-04 | Evan C. Unger | Solid porous matrices and methods of making and using the same |
-
1999
- 1999-09-16 GB GBGB9921954.5A patent/GB9921954D0/en not_active Ceased
-
2000
- 2000-08-03 NZ NZ517631A patent/NZ517631A/en unknown
- 2000-08-03 MX MXPA02002859A patent/MXPA02002859A/es unknown
- 2000-08-03 AU AU68363/00A patent/AU777763B2/en not_active Ceased
- 2000-08-03 CA CA002385063A patent/CA2385063A1/en not_active Abandoned
- 2000-08-03 SK SK345-2002A patent/SK3452002A3/sk unknown
- 2000-08-03 HU HU0202621A patent/HUP0202621A2/hu unknown
- 2000-08-03 IL IL14840900A patent/IL148409A0/xx unknown
- 2000-08-03 JP JP2001522973A patent/JP2003509355A/ja not_active Withdrawn
- 2000-08-03 EA EA200200369A patent/EA005308B1/ru not_active IP Right Cessation
- 2000-08-03 CZ CZ2002943A patent/CZ2002943A3/cs unknown
- 2000-08-03 CN CNB008129525A patent/CN1177583C/zh not_active Expired - Fee Related
- 2000-08-03 EP EP00956409A patent/EP1212040A1/en not_active Withdrawn
- 2000-08-03 WO PCT/EP2000/007679 patent/WO2001019338A1/en not_active Application Discontinuation
- 2000-08-03 BR BR0014063-5A patent/BR0014063A/pt not_active IP Right Cessation
- 2000-08-03 PL PL00353954A patent/PL353954A1/xx not_active Application Discontinuation
- 2000-08-03 KR KR1020027003498A patent/KR20020059405A/ko not_active Application Discontinuation
-
2002
- 2002-03-01 ZA ZA200201743A patent/ZA200201743B/en unknown
- 2002-03-15 NO NO20021306A patent/NO20021306L/no not_active Application Discontinuation
- 2002-11-26 HK HK02108529.1A patent/HK1047227A1/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU777763B2 (en) | 2004-10-28 |
| CN1374858A (zh) | 2002-10-16 |
| CN1177583C (zh) | 2004-12-01 |
| WO2001019338A1 (en) | 2001-03-22 |
| EA200200369A1 (ru) | 2002-08-29 |
| EP1212040A1 (en) | 2002-06-12 |
| AU6836300A (en) | 2001-04-17 |
| SK3452002A3 (en) | 2002-08-06 |
| ZA200201743B (en) | 2003-05-28 |
| CZ2002943A3 (cs) | 2002-08-14 |
| JP2003509355A (ja) | 2003-03-11 |
| NO20021306D0 (no) | 2002-03-15 |
| KR20020059405A (ko) | 2002-07-12 |
| GB9921954D0 (en) | 1999-11-17 |
| IL148409A0 (en) | 2002-09-12 |
| CA2385063A1 (en) | 2001-03-22 |
| MXPA02002859A (es) | 2003-07-21 |
| EA005308B1 (ru) | 2004-12-30 |
| NO20021306L (no) | 2002-04-24 |
| BR0014063A (pt) | 2004-06-29 |
| HK1047227A1 (zh) | 2003-02-14 |
| PL353954A1 (en) | 2003-12-15 |
| NZ517631A (en) | 2004-01-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2001026693A3 (en) | Manufacture of polyglutamate-therapeutic agent conjugates | |
| AU2002305099A1 (en) | Fatty alcohol drug conjugates | |
| TJ275B (en) | Derivatives of cyclodextrins exhibiting enhenced aqueous solubility and the use thereof | |
| MY125978A (en) | Admantane derivatives | |
| CA2289202A1 (en) | Solid pharmaceutical formulations containing a physical mixture of sulfoalkyl ether cyclodextrin and a therapeutic agent | |
| WO2001070275A3 (en) | Polyglutamic acid-camptothecin conjugates and methods of preparation | |
| DK1036058T3 (da) | Adamantanderivater | |
| DK1036059T3 (da) | Adamantanderivater | |
| IL154888A0 (en) | Topical composition containing at least one vitamin d or one vitamin d analogue and at least one corticosteroid | |
| ATE349976T1 (de) | Mikrostruktur-stentstruktur | |
| EP0960107A4 (ru) | ||
| AU2002366042A1 (en) | Solid dispersions containing substituted cyclodextrin and insoluble drug and their preparations | |
| IL150225A0 (en) | Lipopeptides, pharmaceutical compositions containing the same and methods for the production thereof | |
| MXPA02008801A (es) | Derivados de indol, proceso para la preparacion de los mismos y su uso. | |
| AP9901534A0 (en) | Pharmaceutical formulations. | |
| SG146442A1 (en) | Sulphonamide derivatives, their preparation and use as medicaments | |
| CA2294783A1 (fr) | Compositions pharmaceutiques administrables par voie orale, comprenant une substance active et une cyclodextrine | |
| AU5186799A (en) | Peptides of il-2 and derivatives thereof and their use as therapeutic agents | |
| CY2261B1 (en) | Cytotoxic amino sugar and relatd sugar derivativesof indolopyrrolocarbazoles | |
| AU2003297199A1 (en) | Human chondroitinase glycoprotein (chasegp), process for preparing the same, and pharmaceutical compositions comprising thereof | |
| WO1999044608A8 (en) | New use | |
| PT1107793E (pt) | Conjugados de dextrano-leptina, composicoes farmaceuticas e processos relacionados | |
| HUP0202729A2 (hu) | Ösztramusztin-foszfátot és aminosavakat tartalmazó, parenteralis felhasználásra szolgáló készítmények | |
| HUP0202621A2 (hu) | Javított farmakológiai tulajdonságokkal rendelkező, parenteralis felhasználásra szolgáló ösztramusztin-foszfát készítmények | |
| HUP0300185A2 (en) | Formulations for parenteral use of estramustine phosphate and sulfoalkyl ether cyclodextrins |